Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Jarno Kivioja, MSc, Angeliki Thanasopoulou, PhD, Mika Kontro, MD, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Juerg Schwaller, MD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 4711.

https://doi.org/10.1182/blood.V128.22.4711.4711

Published: 2016

Journal Articles

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Mika Kontro, MD, Samuli Eldfors, MSc, Muntasir Mamun Majumder, MSc,MPharm, Alun Parsons, MSc, Tea Pemovska, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD

Blood (2015) 126 (23): 2462.

https://doi.org/10.1182/blood.V126.23.2462.2462

Published: 2015

Journal Articles

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Muntasir Mamun Majumder, MSc,MPharm, Raija Silvennoinen, MD, Pekka Anttila, MD, David Tamborero, PhD, Samuli Eldfors, MSc, Juha Lievonen, MD, Riikka J Karjalainen, Heikki Kuusanmäki, MSc, Alun Parsons, Minna Suvela, Kimmo Porkka, MD PhD, Caroline Heckman

Blood (2015) 126 (23): 3006.

https://doi.org/10.1182/blood.V126.23.3006.3006

Published: 2015

Journal Articles

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Riikka Karjalalainen, Tea Pemovska, Muntasir Mamun Majumder, Bhagwan Yadav, Jing Tang, Mika Kontro, Bjørn Gjertsen, MD PhD, Alun Parsons, Minna Suvela, Kimmo Porkka, Tero Aittokallio, Olli Kallioniemi, Krister Wennerberg, Jonathan Knowles, Caroline Heckman

Blood (2015) 126 (23): 867.

https://doi.org/10.1182/blood.V126.23.867.867

Published: 2015

Journal Articles

Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma

Raija Silvennoinen, MD, Muntasir Mamun Majumder, MSc,BPharm, David Tamborero, PhD, Pekka Anttila, MD, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjaana Säily, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 646.

https://doi.org/10.1182/blood.V124.21.646.646

Published: 2014

Journal Articles

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Pekka Antilla, David Tamborero, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjanna Säily, Bhagwan Yadav, MSc, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2046.

https://doi.org/10.1182/blood.V124.21.2046.2046

Published: 2014

Journal Articles

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Heikki Kuusanmäki, MSc, Hanna Rajala, MD PhD, Arjan van Adrichem, Muntasir Mamun Majumder, MSc,BPharm, Emma I Andersson, MSc, Krister Wennerberg, PhD, Satu Mustjoki, MDPhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 1771.

https://doi.org/10.1182/blood.V124.21.1771.1771

Published: 2014

Journal Articles

Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

David Tamborero, PhD, Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Pekka Anttila, MD, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, BSc, Marjanna Säily, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3351.

https://doi.org/10.1182/blood.V124.21.3351.3351

Published: 2014

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

Journal Articles

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

Jarno Kivioja, MSc, Mika Kontro, MD, Angeliki Thanasopoulou, PhD, Muntasir Mamun Majumder, MSc,BPharm, Bhagwan Yadav, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Juerg Schwaller, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2160.

https://doi.org/10.1182/blood.V124.21.2160.2160

Published: 2014

Journal Articles

The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies

Ashwini Kumar, MRes, Muntasir Mamun Majumder, MSc, Jesus María Lopez Martí, Alun Parsons, MSc, Pirkko Mattila, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2203.

https://doi.org/10.1182/blood.V124.21.2203.2203

Published: 2014

Journal Articles

High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1 -Positive Leukemia

Paavo Pietarinen, MSc, Muntasir Mamun Majumder, MSc, Disha Malani, MSc, Astrid Murumägi, PhD, Tea Pemovska, MSc, Perttu Koskenvesa, MD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline A. Heckman, PhD, Satu Mustjoki, MD, PhD, Kimmo Porkka, MD, PhD

Blood (2013) 122 (21): 2719.

https://doi.org/10.1182/blood.V122.21.2719.2719

Published: 2013

Journal Articles

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Mika Kontro, MD, Kimmo Porkka, MD, PhD, Olli Kallioniemi, MD, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2013) 122 (21): 1668.

https://doi.org/10.1182/blood.V122.21.1668.1668

Published: 2013

Journal Articles

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Blood (2013) 122 (21): 482.

https://doi.org/10.1182/blood.V122.21.482.482

Published: 2013

Journal Articles

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Blood (2012) 120 (21): 288.

https://doi.org/10.1182/blood.V120.21.288.288

Published: 2012

Journal Articles

Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib

Mika Kontro, MD, Caroline Heckman, PhD, Evgeny Kulesskiy, MSc, Tea Pemovska, MSc, Maxim Bespalov, PhD, Samuli Eldfors, MSc, Elonen Erkki, MD, PhD, Riikka Karjalainen, MSc, Jonathan Knowles, PhD, Disha Malani, MSc, Muntasir Mamun Majumder, MSc, John Patrick Mpindi, MSc, PhD, Astrid Murumägi, PhD, Satu Mustjoki, MD, PhD, Laura Turunen, MSc, Maija Wolf, PhD, Kimmo Porkka, MD, PhD, Krister Wennerberg, PhD, Olli Kallioniemi, MD, PhD

Blood (2011) 118 (21): 2487.

https://doi.org/10.1182/blood.V118.21.2487.2487

Published: 2011

NARROW

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies

High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1 -Positive Leukemia

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only